Aevi Genomic Medicine (NASDAQ: GNMX) is one of 95 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Aevi Genomic Medicine to similar businesses based on the strength of its valuation, dividends, analyst recommendations, profitability, earnings, institutional ownership and risk.

Insider and Institutional Ownership

20.8% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 15.2% of Aevi Genomic Medicine shares are held by insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Aevi Genomic Medicine and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Aevi Genomic Medicine N/A -$37.80 million -1.35
Aevi Genomic Medicine Competitors $224.58 million $58.11 million -1.04

Aevi Genomic Medicine’s competitors have higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Aevi Genomic Medicine has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine’s competitors have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Aevi Genomic Medicine and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aevi Genomic Medicine 0 1 1 0 2.50
Aevi Genomic Medicine Competitors 166 554 1216 16 2.55

Aevi Genomic Medicine presently has a consensus price target of $4.25, suggesting a potential upside of 207.97%. As a group, “Biotechnology” companies have a potential upside of 53.21%. Given Aevi Genomic Medicine’s higher probable upside, research analysts clearly believe Aevi Genomic Medicine is more favorable than its competitors.


This table compares Aevi Genomic Medicine and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aevi Genomic Medicine N/A -125.94% -106.93%
Aevi Genomic Medicine Competitors -912.91% -186.15% -28.31%


Aevi Genomic Medicine competitors beat Aevi Genomic Medicine on 8 of the 12 factors compared.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with's FREE daily email newsletter.